ASTX727, Venetoclax, and Gilteritinib
A Phase I/II Study of ASTX727, Venetoclax, and Gilteritinib for Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome With an Activating FLT3 Mutation
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 42 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Tags
- BCL-2 Inhibitor, Cytidine Deaminase Inhibitor (CDAi), Nucleoside Metabolic Inhibitor, Tyrosine Kinase (TK) Inhibitor
- Trial Type
- Treatment
- Last Update
- 3 weeks ago
- SparkCures ID
- 1507
- NCT Identifier
- NCT05010122
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.